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Abstract
Background Early tumor recurrence after curative resection typically indicates a poor prognosis. The objective of the current
study was to investigate the risk factors, treatment, and prognosis of early recurrence of neuroendocrine tumor (NET) liver
metastasis (NELM) after hepatic resection.
Methods A total of 481 patients who underwent curative-intent resection for NELM were identified from a multi-
institutional database. Data on clinicopathological characteristics, intraoperative details, and outcomes were docu-
mented. The optimal cutoff value to differentiate early and late recurrence was determined to be 3 years based on
linear regression.
Results With a median follow-up of 60 months, 223 (46.4%) patients developed a recurrence, including 158 (70.9%) early and
65 (29.1%) late recurrences. On multivariable analysis, pancreatic NET, primary tumor lymph node metastasis, and a micro-
scopic positive surgical margin were independent risk factors for early intrahepatic recurrence. While recurrence patterns and
treatments were comparable among patients with early and late recurrences, early recurrence was associated with worse disease-
specific survival than late recurrences (10-year NELM-specific survival, 44.5 vs 75.8%, p < 0.001). Among the 34 (21.5%)
patients who underwent curative treatment for early recurrence, post-recurrence disease-specific survival was better than non-
curatively treated patients (10-year NELM-specific survival, 54.2 vs 26.3%, p = 0.028), yet similar to patients with late recur-
rences treated with curative intent (10-year NELM-specific survival, 54.2 vs 37.4%, p = 0.519).
Conclusions Early recurrence after surgery for NELM was associated with the pancreatic type, primary lymph node metastasis,
and extrahepatic disease. Re-treatment with curative intent prolonged survival after recurrence, and therefore, operative inter-
vention even for early recurrences of NELM should be considered.
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Introduction
Neuroendocrine tumors (NET) are a rare group of hormone-
secreting neoplasms arising from a variety of neuroendocrine cell
types within the gastroenteropancreatic and bronchopulmonary
systems. Although NETs are mostly considered to be indolent,
these neoplasms can display malignant behavior with develop-
ment of metastatic disease. Furthermore, NETs can cause severe
hormonal symptoms and dysfunction of involved organs.1
Approximately 40–85% of patients with NET have synchronous
or metachronous neuroendocrine liver metastasis (NELM), and
many of these patients have constitutional symptoms and worse
prognoses.1 Specifically, the 5-year survival of patients with
NELM ranges from 13 to 54% compared with 75–99% for pa-
tients with non-metastatic NET.2–4 Among patients with
NELM, surgical resection is the only curative option, yet
is only feasible in roughly 20–40% of cases.5 Recurrence
after surgery is common and decreases both quality of life
and long-term survival of patients. Intrahepatic recurrence
following initial curative hepatectomy for NELM can be as
high as 70–94% at 5 years.6–9 Therefore, appropriate man-
agement of recurrence is central to improve prognosis of
patients after NELM resection.
Shorter time to recurrence has been associated with a worse
prognosis after resection of hepatocellular carcinoma (HCC)
10–13 and colorectal liver metastasis (CRLM), 14–16 yet has not
been well defined for NELM. The management of recurrent
tumors may also be limited and varied with different therapeu-
tic benefits. For example, post-recurrence outcome following
repeat hepatectomy for early versus late recurrence was much
worse among HCC patients, but was similar among patients
with CRLM.12, 14 In NELM, the correlation between time to
recurrence after hepatic resection and patient outcomes has
not been specifically investigated. As such, the objective of
the current study was to define the time course of recurrence
among patients undergoing curative-intent resection of
NELM. More specifically, we sought to identify risk factors
of early recurrence, as well as characterized the treatment and




A total of 548 patients undergoing simultaneous or staged
partial hepatectomy for NELM from 1990 to 2015 were iden-
tified from a multi-institutional database. Data from Johns
Hopkins Hospital, Baltimore, MD; Scientific Institute San
Raffaele, Vita-Salute San Raffaele University, Milan, Italy;
Stanford University, Stanford, CA; University of Virginia,
Charlottesville, VA; Washington University, School of
Medicine, St Louis, MO; Curry Cabral Hospital, Lisbon,
Portugal, and Emory University, Atlanta, GA were included.
All NELM diagnoses were confirmed histologically; 63 pa-
tients with macroscopic positive surgical margins (R2 resec-
tion) were excluded. Moreover, four patients who died within
30 days after hepatic surgery (in hospital death, 0.8%) were
also excluded. Therefore, a total of 481 patients undergoing
R0/R1 resection for NELM were included in the analytic co-
hort. The Institutional Review Boards of each participating
institution approved the study.
Clinical Data Collection and Follow-Up
Demographic and clinicopathological variables were collect-
ed for each patient including the characteristics of the primary
and hepatic metastatic tumor as well as the operative details
for both the primary tumor and NELM (types and extent). The
type of hepatic resection was categorized as minor or major
resection according to the consensus classification.17 Major
hepatectomy was defined as the resection of three or more
segments (right hepatectomy, left hepatectomy, extended right
hepatectomy, extended left hepatectomy, and any
trisegmentectomy), whereas minor resection included resec-
tion of two or fewer segments and nonanatomic wedge resec-
tion according to the classification of Couinaud. Data regard-
ing receipt of adjuvant octreotide treatment, chemo- and ra-
diotherapy were recorded.
Recurrence was defined as suspicious imaging findings or
a biopsy-proven tumor. Sites of recurrence were categorized
as intrahepatic, extrahepatic, or both intra- and extrahepatic.
Treatments of recurrent NELM were categorized as curative-
intent surgery and non-curative therapies. Curative-intent sur-
gery consisted of repeated resection, ablation, or both. Non-
curative treatments were individualized for patients with ad-
vanced recurrent disease and included somatostatin analog
therapy, systemic cytotoxic chemotherapy, and intra-arterial
therapies (IAT).
Optimal Cutoff Value Between Early and Late
Recurrence
Recurrence rate was evaluated at 1-year intervals to determine
the optimal cutoff value to distinguish between early and late
recurrence (Fig. 1). Recurrence was subsequently divided into
two periods according to the slope of the curves identified
with linear regression. The function of the two lines was
y = 22.433–5.75x and y = 5.6214–0.55x, respectively. The
intercept value of the two lines was 3.2 years. Therefore,
3 years was defined as the optimal cutoff value to dif-
ferentiate early and late recurrence of NELM in the
current study (Fig. 1).
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Statistical Analysis
NELM disease-specific survival and recurrence-free survival
were calculated from the date of the initially curative-intent
surgery for NELM. OS after the first recurrence was calculat-
ed from the date of recurrence after initial surgery for NELM.
Continuous variables were expressed as medians with inter-
quartile ranges (IQR) and compared with the Mann-Whitney
U test. Categorical variables were expressed as number and
percentages and compared with Chi-squared test or Fisher’s
exact test. Kaplan–Meier curves with log-rank tests were used
to compare survival. Univariate and multivariable logistic re-
gression models were used to determine factors associated
with early recurrence following initial hepatic resection.
Relative risks were expressed as hazard ratios (HR) and 95%
confidence intervals (CI). Variables with a p value <0.1 by
univariate analysis were entered into the multivariable model.
Two-tailed p value <0.05 was considered statistically signifi-




Among the 481 patients, NELM was synchronous with the
primary NET in 285 (59.3%) patients. The pancreas (n = 203,
42.2%) were the most common site of primary NET, followed
by small bowel (n = 149, 31%), colon (n = 31, 6.4%), and
lungs (n = 26, 5.4%). The majority of patients had more than
50% liver involvement (n = 347, 72.1%), and half of the
patients had bilateral hepatic disease (n = 245, 50.9%).
Extrahepatic disease was present in 46 (9.6%) patients at the
time of NELM diagnosis. The proportion of patients with an
R0 resection was 77.3% (n = 372). Major hepatectomy was
performed in 213 (44.3%) patients. Although the majority of
patients did not receive any preoperative treatment, a small
number did receive octreotide (n = 90, 18.7%) or systemic
chemotherapy (n = 36, n = 7.5%). After the initial hepatic
resection, one third of patients received adjuvant therapy with
either a somatostatin analog (n = 114, 23.7%) or systemic
chemotherapy (n = 50, 10.4%).
Outcome and Recurrence
With a median follow-up time of 60 months, 89 (18.5%) pa-
tients died of disease progression; 161 (33.5%) patients were
alive with disease; and 202 (42%) patients were alive with no
evidence of disease. During follow-up, recurrence was noted
in 223 (46.4%) patients, including 158 patients with an early
(70.9% of recurrence, ≤3 years after hepatic resection) and 65
patients with a late recurrence (29.1% of recurrence, >3 years
after hepatic resection). The cumulative incidence of recur-
rence at 1, 3, 5, and 10 years was 19.6, 38.0, 47.5, and
59.6%, respectively (Fig. 2a).
Compared with patients who were recurrence free for
3 years after curative-intent hepatic resection for NELM, early
recurrence occurred more commonly in younger patients with
pancreatic and a node positive primary tumor, as well as
among patients with >50% liver involvement, an R1 resection
and those patients who received pre- or post-operative chemo-
therapy (Table 1).
The 3-, 5-, and 10-year NELM-specific survival among the
entire cohort was 93.9, 88.2, and 72.9%, respectively (Fig.
2a). Perhaps not surprising, survival was worse among pa-
tients with an early versus late recurrence (10-year NELM-
specific survival rate, 44.5 vs 75.8%, p < 0.001, Fig. 2b). Of
note, the recurrence pattern was, however, not different among
patients who experienced an early versus late recurrence (Fig.
2c).
Risk Factors Associated with Early Recurrence
On multivariable analysis, pancreatic versus gastrointestinal
NET (HR 2.1, 95% CI 1.4–4.0; p = 0.033), node positive
primary NET (HR 5.1, 95% CI 2.5–10.3; p < 0.001), and
extrahepatic disease at diagnosis of NELM (HR 3.1, 95% CI
1.1–8.6; p = 0.027) were independent risk factors associated
with early Bany-site^ recurrence following curative-intent he-
patic resection for NELM (Table 2). A separate multivariable
analysis was then performed that included patients who expe-
rienced intrahepatic-only recurrence. In this analysis, pancre-
atic versus gastrointestinal NET (HR 2.9, 95% CI 1.5–5.8;
p = 0.002), primary tumor lymph node metastasis (HR 3.3,
95% CI 1.7–6.4; p < 0.001), and a microscopic positive sur-
gical margin (HR 2.0, 95% CI 1.0–3.9; p = 0.044) were
Fig. 1 Tumor recurrence after hepatic resection for NELM stratified at 1-
year intervals. Recurrence was divided into two periods according to the
slope of the curves identified with linear regression. Based on the inter-
cept value of the two lines being 3.2 years, 3 years was utilized as the
cutoff to differentiate early versus late recurrence
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independently associated with early intrahepatic recurrence
following curative-intent hepatic resection (Table 3).
Outcome of Early Versus Late Recurrence
In total, 184 (82.5%) patients had available information on
treatment of recurrence. Fifty-two (28.3%) patients underwent
a curative-intent treatment for recurrence including re-
resection and/or ablation. The median time from diagnosis
of recurrence to curative retreatment was 103 days (IQR, 4–
752 days). The majority (n = 48, 92.3%) of these patients
developed intrahepatic-only recurrence at the time of
retreatment, whereas 4 (7.7%) of them underwent curative
resection/ablation for both intra- and extrahepatic recurrence.
Specifically, 34 (21.5%) patients underwent curative treatment
for early recurrence. Interestingly, the proportion of patients
who were offered repeat curative-intent treatment with a late
recurrence was comparable (n = 18, 27.7%). Disease-specific
survival among patients with an early recurrence was im-
proved following repeat curative versus non-curative treat-
ment (10-year NELM-specific survival, 54.2 vs 26.3%,
p = 0.028, Fig. 3a). Furthermore, curative treatment for recur-
rent NELM achieved similar disease-specific survival and
recurrence-free survival among patients who had an early ver-
sus late recurrence (10-year NELM-specific survival, 54.2 vs
37.4%, p = 0.519, Fig. 3b; 5-year recurrence, 75.4 vs 49.7%,
p = 0.305, Fig. 3c).
Overall, patients who experienced early recurrence had
similar NELM-specific survival after the recurrence compared
with patients who developed a late recurrence. NELM-
specific survival remained comparable among patients who
had early versus late recurrence when considering either
intrahepatic-only recurrence (10-year NELM-specific surviv-
al, 50.3 vs 42.4%, p = 0.723, Fig. 4a) or extra- ± intrahepatic
recurrence (10-year NELM-specific survival, 12.2 vs 37.5%,
p = 0.189, Fig. 4b).
Discussion
Curative liver resection and debulking surgery are recom-
mended for the treatment of many patients with NELM.5, 18
Surgical extirpation of NELM can often lead to both symp-
tomatic relief, as well as improved long-term survival. In fact,
even the presence of extensive bilateral hepatic or extrahepatic
disease are not absolute contraindications to liver resection,
which is generally different from the treatment of other types
of primary and secondary liver malignancies.5 Although he-
patic resection is the only curative treatment for NELM, the
high incidence of recurrence has led some clinicians to ques-
tion the benefit of surgery.19–21 In the current study, the inci-
dence of recurrence after curative hepatic resection of NELM
was 46.4%. More specifically, the majority (70.9%) of recur-
rences occurred within the first 3 years (early recurrence),
while only 29.1% of patients recurred beyond 3 years follow-
ing hepatic surgery. Early intrahepatic recurrence was more
common among patients with a pancreatic primary, nodal me-
tastasis, as well as a microscopic positive hepatic resection
margin at the time of NELM surgery. In turn, early recurrence
was associated with worse overall disease-specific survival.
Of note, curative surgery even for early recurrent tumor was
associated with an improved post-recurrence survival, which
was comparable to the outcomes achieved after curative treat-
ment of late recurrences. These findings may have important
implications, as the data highly suggest that repeat resection
and/or ablation should be strongly considered in the treatment
of early recurrent NELM, even in the presence of extrahepatic
disease.
Fig. 2 a Cumulative disease-specific survival and recurrence from the
time of first hepatic surgery for NELM. b NELM-specific survival of
patients in no recurrence group, early recurrence group, and late recur-
rence group from the time of first hepatic surgery. c Sites of recurrence
stratified by early versus late recurrence
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The term Bearly recurrence^ has been defined very differ-
ently in the literature for various hepatic tumors. For example,
for patients withHCC, a cutoff of 6months, 1 year, and 2 years
has been proposed, 10–13, 22, 23 while 6 months, 8 months,
1 year, 1.5 years, and 2 years have been proposed as cutoff
values to define Bearly recurrence^ after curative resection of
Table 1 Clinical and
pathological characteristics of
patients who developed
recurrence within 3 years and
who were 3-year recurrence free
following curative-intent surgery









Age (years) 56 (48–65) 59 (50–68) 0.022
Male gender 83 (52.5%) 164 (50.8%) 0.771
Race 0.980
White 137 (86.7%) 281 (87.0%)
Black 11 (7.0%) 23 (7.1%)
Other 10 (6.3%) 19 (5.9%)
Symptomatic 112 (70.9%) 208 (64.4%) 0.181
Primary tumor characteristics
Location of primary NET 0.024
Gastrointestinal 61 (38.6%) 147 (45.5%)
Pancreas 80 (50.6%) 123 (38.1%)
Other 17 (10.8%) 53 (16.4%)
Functional status 0.255
Non-functional 137 (86.7%) 264 (81.7%)
Functional 17 (10.8%) 48 (14.9%)
Grade of differentiation 0.144
Well 59 (37.3%) 155 (48.0%)
Moderate 33 (20.9%) 53 (16.4%)
Poor 19 (12.0%) 34 (10.5%)
Lymph node status <0.001
N0 36 (22.8%) 149 (46.1%)
N1 98 (62.0%) 130 (40.2%)
Liver metastases characteristics
Synchronous disease 102 (64.6%) 183 (56.7%) 0.137
Liver involvement 0.025
<50% 21 (13.3%) 75 (23.2%)
≥50% 119 (75.3%) 228 (70.6%)
Bilobar disease 86 (54.4%) 159 (49.2%) 0.929
Extrahepatic disease at
diagnosis
21 (13.3%) 25 (7.7%) 0.068
Surgical procedures
Types of hepatectomy 0.001
Minor resection 102 (64.5%) 154 (47.7%)
Major resection 54 (34.2%) 159 (49.2%)
Pre-hepatectomy treatment 0.031
Octreotide 23 (14.6%) 67 (20.7%)
Chemotherapy 18 (11.4%) 18 (5.6%)
None 117 (74.1%) 238 (73.7%)
Intraoperative ablation 43 (27.2%) 56 (17.3%) 0.016
Margin status <0.001
R0 104 (65.8%) 268 (83.0%)
R1 54 (34.2%) 55 (17.0%)
Adjuvant therapy 0.002
Octreotide 41 (25.9%) 73 (22.6%)
Chemotherapy 27 (17.1%) 23 (7.1%)
None 76 (48.1%) 190 (58.8%)
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CRLM.14–16, 24–27 The optimal time point to differentiate be-
tween early and late recurrence after curative hepatic resection
for NELM remains, however, undefined. In the current study,
3 years was proposed as the appropriate cutoff to categorize
patients as early versus late recurrence. Unlike previous
studies that utilized arbitrary cutoff values, we empirically
defined the time course of recurrence using a mathematical
model (Fig. 1). While the incidence of recurrence was highest
in the first year after liver surgery (17.7%), the slope of the
curves associated with the time to recurrence had an intercept
Table 2 Risk factors for early
Bany-site^ recurrence of
neuroendocrine liver metastasis
(NELM) after curative-intent sur-
gery on univariate and multivari-
able analysis
Parameters Univariate analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Patient characteristics
Age (≤70/>70) 2.3 (1.2–4.2) 0.010 1.7 (0.7–4.2) 0.219
Gender (male/female) 0.9 (0.6–1.4) 0.717
Primary tumor characteristics
Location of primary NET
Gastrointestinal Ref. Ref.
Pancreas 1.6 (1.0–2.4) 0.032 2.1 (1.1–4.0) 0.033






Moderate 1.5 (0.8–2.8) 0.237 0.9 (0.4–2.2) 0.862
Poor 1.6 (1.0–2.8) 0.068 1.7 (0.8–3.5) 0.169
Lymph node status <0.001 <0.001
N0 Ref. Ref.
N1 3.1 (2.0–4.9) 5.1 (2.5–10.3)
Liver metastases characteristics
Synchronous metastases 1.4 (0.9–2.0) 0.123
Liver involvement 0.022 0.208
<50% Ref. Ref.
≥50% 1.9 (1.1–3.2) 0.6 (0.2–1.4)
Bilobar disease 1.0 (0.7–1.5) 0.929
Extrahepatic disease at diagnosis 1.8 (1.0–3.4) 0.055 3.1 (1.1–8.6) 0.027
Surgical procedures and perioperative treatments
Pre-hepatectomy treatment
None Ref. Ref.
Octreotide 0.7 (0.4–1.2) 0.178 1.1 (0.5–2.4) 0.840
Chemotherapy 2.0 (1.0–4.1) 0.044 1.8 (0.6–5.1) 0.308
Types of hepatectomy 0.001 0.133
Minor resection Ref. Ref.
Major resection 0.5 (0.3–0.8) 0.6 (0.3–1.2)
Margin status <0.001 0.107
R0 Ref. Ref.
R1 2.5 (1.6–3.9) 1.8 (0.9–3.6)
Intraoperative ablation 1.8 (1.1–2.8) 0.012 1.8 (0.8–4.0) 0.160
Adjuvant therapy
None Ref. Ref.
Octreotide 1.4 (0.9–2.2) 0.153 1.0 (0.5–2.0) 0.908
Chemotherapy 2.9 (1.6–5.4) 0.001 2.0 (0.7–5.5) 0.197
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value of 3.2 years based on linear regression. Specifically, we
empirically demonstrated that the risk of recurrence precipi-
tously dropped following year 3.
Interestingly, early recurrence was more likely to occur
among younger patients. Age has been reported to be
associated with outcomes among cancer patients. For exam-
ple, Graff-Baker et al. reported that age less than 50 was the
only independent risk factor associated with reduced
progression-free and disease-free survival among patients un-
dergoing partial hepatectomy for NELM.18 Interestingly,
Table 3 Risk factors for early
intrahepatic-only recurrence of
neuroendocrine liver metastasis
(NELM) after curative-intent sur-
gery on univariate and multivari-
able analysis
Parameters Univariate analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Patient characteristics
Age (≤70/>70) 2.3 (1.1–4.8) 0.019 1.7 (0.7–4.1) 0.201
Gender (male/female) 0.9 (0.6–1.5) 0.808
Primary tumor characteristics
Location of primary NET
Gastrointestinal Ref. Ref.
Pancreas 1.9 (1.2–3.0) 0.008 2.9 (1.5–5.8) 0.002






Moderate 1.0 (0.5–2.4) 0.914
Poor 1.4 (0.8–2.6) 0.274
Lymph node status <0.001 <0.001
N0 Ref. Ref.
N1 3.4 (2.0–5.7) 3.3 (1.7–6.4)
Liver metastases characteristics
Synchronous metastases 1.5 (0.9–2.4) 0.087 1.3 (0.7–2.5) 0.393
Liver involvement 0.029 0.956
<50% Ref. Ref.
≥50% 2.0 (1.1–3.8) 1.0 (0.4–2.6)
Bilobar disease 0.8 (0.5–1.3) 0.376
Extrahepatic disease at diagnosis 1.2 (0.5–2.9) 0.668
Surgical procedures and perioperative treatments
Pre-hepatectomy treatment
None Ref.
Octreotide 0.6 (0.3–1.1) 0.107
Chemotherapy 1.7 (0.8–3.7) 0.172
Types of hepatectomy 0.005 0.419
Minor resection Ref. Ref.
Major resection 0.5 (0.3–0.8) 0.7 (0.4–1.5)
Margin status <0.001 0.044
R0 Ref. Ref.
R1 2.9 (1.8–4.8) 2.0 (1.0–3.9)
Intraoperative ablation 1.9 (1.1–3.2) 0.013 1.9 (0.9–4.0) 0.121
Adjuvant therapy
None Ref. Ref.
Octreotide 1.8 (1.1–3.0) 0.032 1.1 (0.5–2.3) 0.811
Chemotherapy 2.9 (1.4–6.1) 0.004 1.8 (0.7–4.9) 0.258
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younger patient age has similarly been associated with a more
aggressive tumor phenotype and worse prognosis for other
cancers including colorectal cancer.28, 29 The reason for a
worse prognosis is undoubtedly multifactorial and related, in
part, to worse tumor biology. To this point, early recurrence
was also more common among patients with aggressive pri-
mary NET features, such as a pancreatic primary tumor site as
well as primary NET lymph node metastasis. On univariate
analysis, receipt of pre- and postoperative chemotherapy was
similarly associated with early recurrence. This association
may have been confounded, as patients who received systemic
therapy were more likely to have advanced disease. In fact,
receipt of systemic chemotherapy was not associated with
early recurrence on multivariate analysis. Rather, consist with
previous studies, 6, 7, 30, 31 primary NETcharacteristics includ-
ing pancreatic NET, primary NET nodal metastasis, and the
presence of extrahepatic disease at NELM diagnosis were
independently associated with early recurrence. For patients
with early intrahepatic-only recurrence, R1 resection was also
an important risk factor. Unlike primary and other secondary
liver cancers, NELM tends to grow expansively by pushing
the surrounding liver parenchyma aside rather than invading
it.5 Despite this, an R1 resection should still be the goal of
resection of NELM, as a microscopic positive margin was
associated with an increased risk of intrahepatic recurrence
and may be associated with worse outcome.31.
While early recurrence is often considered a marker of Bbad
biology,^ repeat curative-intent therapy may still be warranted
in certain circumstances. In the present study, among all pa-
tients who recurred, individuals who developed an early re-
currence were treated with curative and non-curative ap-
proaches at similar frequency compared with patients who
developed a late recurrence. Of note, curative treatments for
early recurrent NELM improved survival and achieved com-
parable post-recurrence survival versus patients with a late
recurrence. In fact, post-recurrence disease-specific survival
was comparable among patients with early versus late recur-
rences when considering either intrahepatic-only recurrence
or extra- ± intrahepatic recurrence. Therefore, surgery should
be considered for the treatment of recurrent NELM, even in
the setting of early recurrence.
Fig. 3 aDisease-specific survival after tumor recurrence of patients after
curatively and non-curatively treated early recurrence. b Disease-specific
survival after tumor recurrence of patients with early and late recurrence
after curative treatment. c Cumulative recurrence after second curative
treatment stratified by early versus late recurrence
Fig. 4 aDisease-specific survival after tumor recurrence of patients with
intrahepatic-only early versus late recurrence. b Disease-specific survival
after tumor recurrence of patients with extra- ± intrahepatic stratified by
early versus late recurrence
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The current study had several limitations. Given the retro-
spective nature of the study, residual confounding and selec-
tion bias were possible. In particular, the selection of patients
for repeat curative-intent surgery following recurrence likely
was affected by selection bias. Surgeons undoubtedly chose
patients for repeat curative-intent surgery based on a number
of features that were both measured and unmeasured in the
current study. Notwithstanding this limitation, the data still
strongly suggest that repeat curative-intent surgery for patient
with early recurrence may be both feasible and effective in a
subset of patients. The lack of data collection on perioperative
complications was another limitation of the current study that
did not permit us to assess the safety of initial or repeat NELM
surgery.
In conclusion, recurrence following curative-intent surgery
for NELM occurred in almost half of patients (~46.4%), with
predominantly early recurrence within the first 3 years
(70.9%). Early recurrence at any site after hepatic resection
was strongly associated with the characteristics of the primary
NET (pancreatic type, primary lymph node metastasis, and
extrahepatic disease at presentation). In addition to these fac-
tors, an R1 surgical margin was associated with an increased
risk factor of intrahepatic recurrence. Although early recur-
rence diminished overall survival, re-treatment with curative
intent prolonged survival after recurrence and therefore oper-
ative intervention even for early recurrences of NELM should
be considered.
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